Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsEmpire Bluecross Lerochol Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedEmpire BluecrossPolicy CC-0299

    Lerochol (lerodalcibep-liga) Coverage Criteria

    Customize your policy alerts

    Sign up for Empire Bluecross Policy CC-0299 alerts

    Get alerted when Policy CC-0299 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and coverage of Lerochol, a monthly subcutaneous PCSK9 inhibitor used with diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. It applies to providers requesting initial or continuation therapy and includes clinical criteria, step therapy, quantity limits, and billing codes.

    Policy Summary
    PayerEmpire Bluecross
    PolicyLerochol (lerodalcibep-liga) Coverage Criteria
    Policy CodePolicy CC-0299
    Change TypeModified
    Effective DateJun 23, 2026
    Last ReviewMay 15, 2026
    Next Review DateN/A
    Key ActionDocument that the individual meets an approved high-ASCVD-risk pathway, the applicable LDL-C threshold and risk criteria, and the treatment requirements for initial or continuation therapy.
    SourceLink
    POLICY UPDATE CHANGES

    The policy history reports updated indication wording and LDL threshold criteria.

    The policy history reports updates to the step-therapy tables.

    HCPCS NOC J3490 was removed from the policy coding list.

    ICD-10-CM diabetes mellitus code ranges E10.10-E10.A2, E11.00-E11.A, and E13.00-E13.9 were added.

    The policy history reports addition of step therapy and step-therapy tables.

    1 syringe/28 daysQuantity limit
    ≥55 mg/dLASCVD LDL-C threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ≥70 mg/dLHigh-risk LDL-C threshold
    2Preferred PCSK9 agents
    1 yearApproval duration

    Coverage Criteria

    Initial Therapy

    Initial requests may be approved when ALL of the following are met:

    ALL of the following

    • ONE of

      • HeFH is verified by ONE of the following

        • Presence of a mutation in the LDLR, ApoB, PCSK9, or ARH adaptor protein (LDLRAP1) gene.
        • WHO/Dutch Lipid Clinic Network criteria with a score greater than eight points.
      • History of clinical ASCVD including ONE or more of the following

        • Acute coronary syndrome.
        • Coronary artery disease (CAD).
        • History of myocardial infarction (MI).
        • Stable or unstable angina.
        • Coronary or other arterial revascularization.
        • Stroke.
        • Transient ischemic attack (TIA).
        • Peripheral arterial disease (PAD).
      • Hypercholesterolemia.
    • ONE of the following LDL-C/risk pathways

      • ALL of the following

        • LDL-C is greater than or equal to 55 mg/dL.>= 55 mg/dL
        • Individual has a history of clinical ASCVD.
      • ALL of the following

        • LDL-C is greater than or equal to 70 mg/dL.>= 70 mg/dL
        • ONE of

          • Severe hypercholesterolemia with baseline LDL greater than or equal to 190 mg/dL and HeFH, additional ASCVD risk factors, or coronary calcification.

    Continuation Therapy

    Continuation requests may be approved when ALL of the following are met:

    ALL of the following

    • Individual continues to use Lerochol in combination with maximally tolerated statin therapy, unless contraindication or statin intolerance applies.
    • Individual has achieved LDL-C reduction.

    Statin Therapy, Intolerance, or Contraindication

    The individual meets ONE of the following statin-treatment conditions:

    ONE of

    • Individual is on high-intensity statin therapy or statin therapy at the maximum tolerated dose.

      High-intensity statin therapy is defined as atorvastatin 40 mg or higher or rosuvastatin 20 mg or higher.

    • Individual is statin intolerant based on ONE of the following

      • Inability to tolerate at least two statins, with at least one started at the lowest starting daily dose, demonstrated by adverse effects associated with statin therapy that resolve or improve with dose reduction or discontinuation.
      • Statin-associated rhabdomyolysis or immune-mediated necrotizing myopathy (IMNM) after a trial of one statin.
    • Individual has a contraindication for statin therapy, including but not limited to active liver disease, unexplained persistent elevation of hepatic transaminases, or pregnancy.

    Lerochol may not be approved when used in combination with Leqvio, Praluent, or Repatha.

    Lerochol may not be approved when the coverage criteria above are not met or for all other indications.

    Billing and Diagnosis Coding

    HCPCSHCPCS
    C9399Unclassified drugs or biologicals [when specified as Lerochol (lerodalcibep-liga)]
    J3590Unclassified biologics [when specified as Lerochol (lerodalcibep-liga)]
    ICD-10 DiagnosisICD-10
    E10.10-E10.A2Type 1 diabetes mellitus
    E11.00-E11.AType 2 diabetes mellitus
    E13.00-E13.9Other specified diabetes mellitus
    E78.0Pure hypercholesterolemia
    E78.011Heterozygous familial hypercholesterolemia [HeFH]
    E78.1Pure hyperglyceridemia
    E78.2Mixed hyperlipidemia
    E78.41-E78.5Other, unspecified hyperlipidemia
    G45.0-G45.9Transient cerebral ischemic attacks and related syndromes
    I20.0-I20.9Angina pectoris
    1–10 of 23
    1/3
    ICD-10 DiagnosisICD-10
    Z83.42Family history of familial hypercholesterolemia
    Z86.73Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
    Z95.5Presence of coronary angioplasty implant and graft
    Z95.820-Z95.828Presence of other vascular implants and grafts
    Z98.61-Z98.62Angioplasty status
    ICD-10 DiagnosisICD-10
    E10.10-E10.A2Type 1 diabetes mellitus
    E11.00-E11.AType 2 diabetes mellitus
    E13.00-E13.9Other specified diabetes mellitus
    E78.0Pure hypercholesterolemia
    E78.011Heterozygous familial hypercholesterolemia [HeFH]
    E78.1Pure hyperglyceridemia
    E78.2Mixed hyperlipidemia
    E78.41-E78.5Other, unspecified hyperlipidemia
    G45.0-G45.9Transient cerebral ischemic attacks and related syndromes
    I20.0-I20.9Angina pectoris
    1–10 of 23
    1/3
    ICD-10 DiagnosisICD-10
    Z83.42Family history of familial hypercholesterolemia
    Z86.73Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits
    Z95.1Presence of aortocoronary bypass graft
    Z95.5Presence of coronary angioplasty implant and graft
    Z95.820-Z95.828Presence of other vascular implants and grafts
    Z98.61-Z98.62Angioplasty status
    HCPCS NOC CodesHCPCS
    C9399HCPCS NOC code for Lerochol
    J3490HCPCS NOC code; added historically for Lerochol and subsequently removed
    J3590HCPCS NOC code added in the current coding review
    Clinical ASCVD
    Clinical ASCVD LDL-C threshold≥55 mg/dL
    Applicable populationIndividuals with a history of clinical ASCVD
    Required pairingLDL-C ≥55 mg/dL and clinical ASCVD history
    High-Risk Primary Prevention
    High-risk primary prevention LDL-C threshold≥70 mg/dL
    Severe hypercholesterolemia pathwayBaseline LDL-C ≥190 mg/dL plus HeFH, additional ASCVD risk factors, or coronary calcification

    Provider Requirements and Action Items

    Documentation Required

    Clinical Criteria Required

    Document the applicable clinical pathway and LDL-C threshold before requesting Lerochol. Initial approval requires high ASCVD risk through an approved pathway and satisfaction of the applicable 2026 ACC/AHA LDL-C criteria. Continuation requires ongoing use with maximally tolerated statin therapy, unless contraindicated or the individual is statin intolerant, and an achieved LDL-C reduction.

    • High-risk pathway: HeFH verified by an LDLR, ApoB, PCSK9, or LDLRAP1 mutation, or a WHO/Dutch Lipid Clinic Network score greater than 8; clinical ASCVD, including acute coronary syndrome, CAD, MI, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, or PAD; or hypercholesterolemia.
    • LDL-C criteria: LDL-C ≥55 mg/dL with a history of clinical ASCVD; LDL-C ≥70 mg/dL with severe hypercholesterolemia (baseline LDL-C ≥190 mg/dL) plus HeFH, additional ASCVD risk factors, or coronary calcification; PREVENTASCVD risk ≥10%; CAC ≥300 AU; or diabetes; or LDL-C ≥100 mg/dL.
    • Approval duration: Initial and continuation approvals may each be granted for 1 year.
    Step Therapy

    Preferred PCSK9 Agent Step Therapy

    Clinical Background

    Lerochol (lerodalcibep-liga) is a PCSK9 inhibitor approved as an adjunct to diet and exercise to reduce LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia. It is administered subcutaneously once monthly. The effect of Lerochol on cardiovascular morbidity and mortality has not been determined.

    Key Definitions

    Familial Hypercholesterolemia
    Familial hypercholesterolemiaAn inherited condition caused by genetic mutations that result in high LDL-C levels at an early age
    Heterozygous FHThe more common form, involving one altered copy of a cholesterol-regulating gene
    Homozygous FHThe rarer, more severe form, involving two altered copies of cholesterol-regulating genes
    Statin Intolerance
    Statin intoleranceOne or more adverse effects associated with statin therapy that resolve or improve with dose reduction or discontinuation
    Complete intoleranceInability to tolerate any dose of a statin

    Initial Therapy Criteria

    Initial Therapy Criteria

    Initial requests may be approved when the individual meets one high-ASCVD-risk pathway and one applicable LDL-C/risk pathway.

    Initial therapy

    • One high-ASCVD-risk pathway

      • HeFH verification

        • The individual has a mutation in the LDLR, ApoB, PCSK9, or LDLRAP1 gene.
        • The individual has a WHO/Dutch Lipid Clinic Network score greater than 8 points.>8 points
      • The individual has a history of clinical ASCVD, including acute coronary syndrome, coronary artery disease, myocardial infarction, stable or unstable angina, coronary or other arterial revascularization, stroke, transient ischemic attack, or peripheral arterial disease.

    Continuation Criteria

    Continuation Therapy Criteria

    Continuation requests may be approved when both continuation criteria are met.

    Continuation therapy

    • Background statin treatment

      • The individual continues to use Lerochol in combination with maximally tolerated statin therapy.
      • The individual has a contraindication to statin therapy or is statin intolerant.
    • Treatment response

      • The individual has achieved LDL-C reduction.

    Step-Therapy Requirements

    StepRequirementApproval condition
    1
    Use a preferred PCSK9 agent before a non-preferred PCSK9 agent when required by the benefit plan.
    For a non-preferred PCSK9 agent, the individual must have an adequate trial and titration of a preferred PCSK9 agent and achieve a suboptimal lipid-lowering response.
    DatePolicy history updateDocumented step-therapy sequence
    05/01/2026
    Step therapy and step-therapy tables added.
    Specific sequence not stated in the document history.
    06/01/2026
    Step-therapy table updates.
    Specific sequence not stated in the document history.
    05/15/2026
    Annual review included step-therapy table updates.
    Specific sequence not stated in the document history.

    Quantity Limits

    Quantity Limit
    Drug and strengthLerochol (lerodalcibep-liga) 300 mg/1.2 mL prefilled syringe
    Quantity limit1 syringe
    Supply intervalPer 28 days
    Policy Summary
    PayerEmpire Bluecross
    PolicyLerochol (lerodalcibep-liga) Coverage Criteria
    Policy CodePolicy CC-0299
    Change TypeModified
    Effective DateJun 23, 2026
    Last ReviewMay 15, 2026
    Next Review DateN/A
    Key ActionDocument that the individual meets an approved high-ASCVD-risk pathway, the applicable LDL-C threshold and risk criteria, and the treatment requirements for initial or continuation therapy.
    SourceLink
    On This Page
    Coverage CriteriaBilling and Diagnosis CodingProvider Requirements and Action ItemsClinical BackgroundKey DefinitionsInitial Therapy CriteriaContinuation CriteriaStep-Therapy RequirementsQuantity Limits
    >= 190 mg/dL baseline LDL
  1. PREVENTASCVD equation of at least 10%.>= 10%
  2. Coronary artery calcium (CAC) greater than or equal to 300 AU.>= 300 AU
  3. Diagnosis of diabetes.
  4. LDL-C is greater than or equal to 100 mg/dL.>= 100 mg/dL
  5. Other qualifying pathwaysPREVENT-ASCVD ≥10%, CAC ≥300 AU, or diabetes
    Additional LDL-C Criterion
    Additional LDL-C threshold≥100 mg/dL
    Applicable pathwayOther LDL-C pathway for initial approval
    Clinical requirementThe individual must have LDL-C of at least 100 mg/dL
    Severe Hypercholesterolemia
    Severe hypercholesterolemia baseline LDL-C≥190 mg/dL
    Associated LDL-C criterionCurrent LDL-C must also be ≥70 mg/dL
    Additional requirementHeFH, additional ASCVD risk factors, or coronary calcification
    PREVENT-ASCVD
    PREVENT-ASCVD qualifying risk≥10%
    Associated LDL-C threshold≥70 mg/dL
    Applicable pathwayPREVENT-ASCVD pathway for initial approval
    Coronary Artery Calcium
    Qualifying coronary artery calcium score≥300 AU
    Associated LDL-C threshold≥70 mg/dL
    Applicable pathwayCAC pathway for initial approval
    Familial Hypercholesterolemia Scoring
    Definite familial hypercholesterolemia>8 points
    Scoring systemWHO/Dutch Lipid Clinic Network criteria
    Use in eligibilityQualifies as HeFH verification when clinical criteria are used
    Familial Hypercholesterolemia Scoring
    Probable familial hypercholesterolemia6–8 points
    Scoring systemWHO/Dutch Lipid Clinic Network criteria
    ClassificationProbable FH
    Familial Hypercholesterolemia Scoring
    Possible familial hypercholesterolemia3–5 points
    Scoring systemWHO/Dutch Lipid Clinic Network criteria
    ClassificationPossible FH
    Familial Hypercholesterolemia Scoring
    Unlikely familial hypercholesterolemia0–2 points
    Scoring systemWHO/Dutch Lipid Clinic Network criteria
    ClassificationUnlikely FH

    Check the member’s benefit plan for preferred-agent requirements before submitting Lerochol. Even when the clinical criteria are met, the plan may require use of one or more preferred agents first; document compliance with the applicable benefit-plan requirement.

    • The benefit plan may require use of a preferred PCSK9 agent or agents when Lerochol is otherwise clinically approvable.
    • Preferred means an agent considered clinically comparable to other agents in the same class or disease category and selected based on clinical evidence and cost effectiveness.
    • A list of preferred PCSK9 agents is available through the plan resource identified in the policy.
    Denial Risk

    Excluded Combinations and Other Indications

    Do not request Lerochol when an exclusion applies. Requests are not approvable when the policy criteria are not met or for indications outside the covered criteria.

    • Do not use Lerochol in combination with Leqvio, Praluent, or Repatha.
    • Requests are not approved when the high-ASCVD-risk pathway and applicable LDL-C criteria are not met.
    • Requests are not approved for all other indications.
    Step Therapy

    Preferred PCSK9 Agent Trial Required

    For a non-preferred PCSK9 agent, document an adequate trial and titration of a preferred PCSK9 agent. The non-preferred request may be approved only when that trial and titration produced a suboptimal lipid-lowering response.

    • Document the preferred PCSK9 agent trial and titration as adequate.
    • Document the resulting suboptimal lipid-lowering response.
    • A list of preferred PCSK9 agents is available through the plan resource identified in the policy.
    Partial intolerance
    Inability to tolerate the dose needed to achieve the individual-specific therapeutic objective
    Minimum Statin Intolerance Trial
    Minimum number of statins attemptedAt least two statins
    Dose requirementAt least one statin must have been attempted at the lowest approved daily dosage
    Clinical characterizationAdverse effects must resolve or improve with dose reduction or discontinuation
  6. The individual has hypercholesterolemia.
  7. One applicable LDL-C/risk pathway

    • Clinical ASCVD pathway

      • LDL-C is greater than or equal to 55 mg/dL and the individual has a history of clinical ASCVD.LDL-C ≥55 mg/dL
    • Severe hypercholesterolemia/high-risk pathway

      • LDL-C is greater than or equal to 70 mg/dL and baseline LDL-C is greater than or equal to 190 mg/dL, with HeFH, additional ASCVD risk factors, or coronary calcification.LDL-C ≥70 mg/dL; baseline LDL-C ≥190 mg/dL
    • PREVENT-ASCVD pathway

      • LDL-C is greater than or equal to 70 mg/dL and the PREVENT-ASCVD equation is greater than or equal to 10%.LDL-C ≥70 mg/dL; PREVENT-ASCVD ≥10%
    • CAC pathway

      • LDL-C is greater than or equal to 70 mg/dL and coronary artery calcium is greater than or equal to 300 AU.LDL-C ≥70 mg/dL; CAC ≥300 AU
    • Diabetes pathway

      • LDL-C is greater than or equal to 70 mg/dL and the individual has a diagnosis of diabetes.LDL-C ≥70 mg/dL
    • Other LDL-C pathway

      • LDL-C is greater than or equal to 100 mg/dL.LDL-C ≥100 mg/dL